A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) - ALXN1210-IgAN-320

Brief description of study

We are doing this study to learn more about the study drug, called ravulizumab, which can also be referred to as ALXN1210, and also to better understand the studied disease and associated health problems. Ravulizumab has already been approved in various countries as a safe and effective therapy for four other conditions under the brand name Ultomiris®, but we now want to explore this medication with IgAN.

Clinical Study Identifier: s24-00620

ClinicalTrials.gov Identifier: NCT06291376

Principal Investigator: Olga Zhdanova.

Other Investigators: Sindhuri Prakash-Polet, Niveda Shekar, Nina J Caplin, Margaret De Oliveira.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies